Array BioPharma sees success in clinical trials

BOULDER — Array BioPharma (Nasdaq: ARRY) experienced stock prices up 7 percent before the market opened following the announcement of positive data from clinical trials.

The third phase of clinical trials of its drug binimetinib combined with encorafenib showed positive results in patients with metastatic melanoma.

Earlier this summer, Array filed new drug applications to the Food and Drug Administration for the combination of the two drugs.

At the time of publication, Array’s stock slid slightly, dropping from $11.82 when the market opened to $10.53 per share.



Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>